SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Enochian Biosciences, Inc. (ENOB) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 10/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ENOB
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.08
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.18 |
$42.77K |
$-1.74M |
-4057.2% |
| 2016 |
$-0.17 |
$0.00 |
$-2.14M |
- |
| 2017 |
$-0.29 |
$0.00 |
$-6.31M |
- |
| 2018 |
$-0.48 |
$0.00 |
$-18.02M |
- |
| 2019 |
$-0.25 |
$0.00 |
$-11.42M |
- |
| 2020 |
$-0.57 |
$0.00 |
$-26.72M |
- |
| 2021 |
$-2.16 |
$0.00 |
$-113.43M |
- |
| 2022 |
$-0.71 |
$0.00 |
$-39.68M |
- |
| 2023 |
$-0.84 |
$0.00 |
$-80.65M |
- |
| 2025 |
$-1.08 |
$0.00 |
$-178.01M |
- |
